查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2003220

球蟲藥市場：按產品類型、劑型、最終用途和分銷管道分類的全球市場預測，2026-2032年

Anticoccidial Drugs Market by Product Type, Form, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，球蟲藥物市場價值將達到 2.5973 億美元，到 2026 年將成長至 2.7492 億美元，到 2032 年將達到 3.8799 億美元，複合年成長率為 5.90%。

主要市場統計數據
基準年 2025 2.5973億美元
預計年份：2026年 2.7492億美元
預測年份 2032 3.8799億美元
複合年成長率 (%) 5.90%

簡單介紹球蟲療法在現代畜牧業健康管理的策略重要性。

在集約化畜牧管理系統中，球蟲藥物在維持消化器官系統健康和生產效率方面仍然發揮核心作用。隨著畜牧業集約化程度的提高，針對性化學預防和治療性介入的作用日益凸顯，以應對可能損害生產力、動物福利和飼料轉換率的疾病威脅。在此背景下，了解球蟲治療的發展趨勢對於獸醫團隊、飼料生產商、監管機構和相關人員至關重要，他們都在努力平衡療效、安全性和永續性。

這將帶來變革性的變化，重塑整個畜牧業球蟲藥物的研發、使用模式和合理使用方式。

近年來，科學、監管和市場因素的共同作用正在改變球蟲療法的研發、分銷和推廣。病原體基因組學和體外藥敏試驗的進步提高了抗藥性的檢測和監測能力，從而能夠開發更有針對性的產品和製定區域性治療策略。同時，對動物福利和主導品質標準的要求迫使生產者重新評估預防措施，並優先考慮能夠減少飼料中藥物添加量的綜合疾病管理方法。

分析美國於 2025 年宣布的關稅對球蟲藥物供應鏈和採購的累積營運和策略影響。

2025年實施的關稅措施對整個球蟲藥物供應鏈產生了連鎖反應，涵蓋了供應、生產投入和分銷環節。對某些藥品活性成分和飼料中間體徵收的進口關稅增加了依賴國際採購的生產商和飼料廠的接收成本。為此，採購團隊正在重新評估其供應商組合，優先考慮替代來源，並加強與契約製造生產商的溝通，以確定可以降低成本的生產週期，從而緩解利潤率下降的影響。

透過整合終端用途、分銷管道、產品類型和配方選擇等方面的關鍵細分洞察，我們支援有針對性的策略方法。

市場區隔闡明了治療需求與推廣障礙之間的交集。基於最終用途，市場研究涵蓋牛、家禽和豬三大領域，其中家禽市場透過不同的生產系統（肉雞和蛋雞）進行了更詳細的分析。這些物種和系統層面的差異導致了給藥時間、給藥策略以及與飼料管理技術的整合方面的差異。飼料添加劑配方和飲用水治療劑在肉雞生產週期和蛋雞管理中採用不同的方法，從而對產品開發和行銷提出了獨特的要求。同一物種內不同治療類別之間的轉換取決於生產規模、生物安全通訊協定以及零售商和加工商的特定要求。

區域洞察聚焦在美洲、歐洲、中東和非洲以及亞太地區的各種因素及其對產品策略的影響。

區域趨勢影響著監管重點、疾病壓力和採購行為。在美洲，生產規模、一體化供應鏈和加工商主導的品質管理系統推動了對穩定、與飼料相容的球蟲藥物的需求。生產商傾向於選擇符合高生產率系統和嚴格食品安全要求的產品。在歐洲、中東和非洲，對某些合成化合物的監管以及對合理使用抗菌劑的高度重視，正促使產品轉向兼顧療效和殘留風險的選擇。在許多歐洲市場，零售商的舉措和以動物福利主導也在舉措著向綜合管理方法的轉變，並減少對預防性用藥的依賴。

來自主要企業的見解，重點關注策略行動、研發重點領域和合作模式，這些都影響著球蟲藥市場的競爭趨勢。

市場參與企業展現出多元化的策略策略，這反映了它們的規模、產品組合廣度和垂直整合程度。大規模跨國動物用藥品公司優先考慮製劑穩定性創新、抗藥性降低技術以及結合診斷和合理用藥方案的綜合服務交付。這些企業投資於全球監管合規能力，以應對不同的殘留標準和註冊要求，並通常採用多通路分銷模式，以涵蓋工業整合商和小規模獨立生產商。中型和區域性生產商則利用接近性飼料廠網路和合約農場叢集的優勢，專注於成本競爭力強的製劑、本地監管專業知識和供應鏈可靠性。

為行業領導者提供實用建議，使其產品開發、商業策略和管理與不斷變化的市場現實保持一致。

產業領導者應優先考慮將產品功效、農場實施和抗藥性管理相結合的綜合方法。投資於診斷和監測方面的夥伴關係將有助於提高治療性介入的針對性，並支持以數據為導向的作物輪作或合併用藥策略，從而維持療效。同時，提高製劑與常用飼料廠工作流程和液體給藥系統的兼容性，可降低推廣門檻，提高給藥準確性。這些技術投資應與獸醫和飼料管理人員的教育計畫結合，以確保正確使用並強化管理原則。

調查方法詳細介紹了為確保研究結果的可靠性和適用性而採用的資料收集、檢驗過程和分析方法。

本研究採用混合方法，結合一手訪談、二手文獻分析和供應鏈圖譜建構全面的證據基礎。一手資料透過對獸醫、飼料廠經理、契約製造生產商和分銷專家的結構化訪談獲得，以了解實際情況和推廣應用的障礙。二手資訊則來自關於球蟲生物學和治療效果的同行評審文獻、監管通告、產品標籤和公開貿易文件，以支持技術和政策背景。

結論總結了從事球蟲領域工作的相關人員面臨的策略挑戰以及實現永續治療效果的途徑。

球蟲藥物領域正受到科學進步、監管壓力、分銷模式轉變和貿易趨勢的重塑。維持療效需要整合產品創新和合理用藥、穩健的供應鏈設計以及有針對性的商業性合作等綜合策略。成功的企業將致力於使製劑研發與臨床實踐相契合，投資於抗藥性監測夥伴關係，並採用既能擴大患者可及性又能保證品質的分銷模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：球蟲藥市場：依產品類型分類

  • 離子載體
    • 拉薩羅
    • 孟寧素
    • 沙利黴素
  • 合成藥物
    • 硝基呋喃
    • 奎諾酮
    • 磺胺類藥物藥物

第9章：球蟲藥市場：依劑型分類

  • 飼料添加劑
  • 液體
  • 預混合料

第10章：球蟲藥市場：依最終用途分類

  • 牛
  • 家禽
    • 肉雞
    • 產蛋母雞
  • 豬

第11章：球蟲藥市場：依通路分類

  • 線上
  • 離線

第12章：球蟲藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：球蟲藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：球蟲藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國球蟲藥市場

第16章：中國球蟲藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alltech, Inc.
  • BASF SE
  • Bayer Aktiengesellschaft
  • Boehringer Ingelheim International GmbH
  • Cargill, Incorporated
  • Ceva Sante Animale
  • DCBL Pharmaceuticals Ltd.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Evonik Industries AG
  • HIPRA SA
  • Huvepharma AD
  • Impextraco NV
  • Intas Pharmaceuticals Limited
  • Kemin Industries, Inc.
  • Lallemand Inc.
  • Merck & Co., Inc.
  • Novus International, Inc.
  • Nutreco NV
  • Phibro Animal Health Corporation
  • Qilu Animal Health Products Co., Ltd.
  • VH Group
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-456C7E8666FE

The Anticoccidial Drugs Market was valued at USD 259.73 million in 2025 and is projected to grow to USD 274.92 million in 2026, with a CAGR of 5.90%, reaching USD 387.99 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 259.73 million
Estimated Year [2026] USD 274.92 million
Forecast Year [2032] USD 387.99 million
CAGR (%) 5.90%

A concise introduction framing the strategic importance of anticoccidial therapies in modern livestock health management

Anticoccidial drugs remain central to maintaining gastrointestinal health and production efficiency across intensively managed livestock systems. As the industry has intensified, the role of targeted chemoprophylaxis and therapeutic interventions has expanded to address disease pressure that would otherwise undermine productivity, animal welfare, and feed conversion outcomes. In this context, understanding the evolving landscape of anticoccidial approaches is essential for veterinary teams, feed manufacturers, regulatory bodies, and commercial stakeholders seeking to balance efficacy, safety, and sustainability.

This report synthesizes recent scientific advances, regulatory movements, distribution channel evolution, and end-use dynamics to provide an integrated view of contemporary anticoccidial practice. It examines how product formulation choices, shifts in species-specific husbandry, and emerging resistance patterns are influencing treatment selection and supply chain decisions. By establishing a clear baseline of current practice and emerging pressures, the analysis supports evidence-based planning for research investment, market entry, and policy engagement.

Throughout the analysis, emphasis is placed on pragmatic implications for decision-makers: how formulation and delivery choices intersect with on-farm workflows, how distribution models affect accessibility and stewardship, and how regulatory and trade developments influence sourcing and manufacturing strategies. The introduction thus frames the subsequent sections that explore transformative shifts, tariff impacts, segmentation insights, regional nuances, competitor behavior, actionable recommendations, methodology, and the overarching conclusions that guide operational and strategic responses.

Transformative shifts reshaping anticoccidial drug development, use patterns, and stewardship across animal agriculture

Recent years have seen a convergence of scientific, regulatory, and market drivers that are transforming how anticoccidial therapies are developed, distributed, and deployed. Advances in pathogen genomics and in vitro susceptibility testing have improved the capacity to detect and monitor resistance, enabling more targeted product development and localized treatment strategies. At the same time, animal welfare imperatives and retailer-driven quality standards are pushing producers to reassess prophylactic approaches and favor integrated disease management practices that reduce blanket medicated feed usage.

Concurrently, the product landscape is evolving. Ionophores continue to be valued for their efficacy and feed-additive compatibility, while synthetic compounds remain critical in therapeutic contexts where resistance or specific lifecycle stages necessitate their use. Formulation innovation-such as improved premixes and stabilized liquids-has increased dosing precision and ease of integration into feed and water systems. Distribution channels are also shifting; direct sales relationships and specialty veterinary channels are strengthening, while digital platforms and online pharmacies expand accessibility and alter purchasing behavior.

Moreover, sustainability and regulatory compliance considerations are driving supply chain reconfiguration. Manufacturers and feed integrators are investing in upstream quality control, traceability, and alternative sourcing to mitigate exposure to trade disruptions and regulatory changes. Taken together, these shifts are recalibrating competitive dynamics, research priorities, and operational practices across the anticoccidial ecosystem, demanding adaptive strategies from pharmaceutical developers, contract manufacturers, feed companies, and veterinary service providers.

Analyzing the cumulative operational and strategic consequences of United States tariffs announced in 2025 on anticoccidial supply chains and procurement

The tariff measures introduced in 2025 have had ripple effects across the supply chains that support anticoccidial drug availability, manufacturing inputs, and distribution economics. Import duties on certain active pharmaceutical ingredients and intermediary feed materials have increased landed costs for manufacturers and feed mills that rely on international sourcing. In response, procurement teams have re-evaluated supplier portfolios, prioritized alternative origins, and escalated conversations with contract manufacturers to identify cost-saving production windows and mitigate margin erosion.

These tariff-driven adjustments have also accelerated nearshoring conversations and investments. Companies with flexible manufacturing footprints have reallocated production or increased inventory buffers to preserve supply continuity. Simultaneously, smaller producers and regional feed integrators have faced more pronounced cost pressures due to limited hedging capabilities, prompting consolidation and strategic partnerships to share scale advantages. Regulatory compliance and customs complexity introduced by tariffs have added administrative overhead, increasing time-to-delivery and influencing ordering cadence.

Importantly, distribution channels have adapted to tariff-induced cost volatility. Direct-sales teams and specialty distributors have intensified value-based conversations with customers, emphasizing formulation benefits and stewardship programs that justify premium pricing. Online pharmacies and digital procurement platforms have helped some buyers source alternative formulations or generics from non-impacted jurisdictions, though quality assurance and regulatory conformity remain primary considerations. Overall, the cumulative impact of tariffs has reshaped sourcing strategies, compelled operational resilience investments, and influenced commercial positioning across the anticoccidial value chain.

Key segmentation insights synthesizing end use, distribution channels, product types, and formulation choices to inform targeted strategic initiatives

Segmenting the market clarifies where therapeutic demand and adoption barriers intersect. Based on end use, the market is studied across cattle, poultry, and swine, with poultry further examined through the distinct production systems of broiler chicken and layer chicken; these species- and system-level differences drive divergent treatment timing, dosing strategies, and integration with feed management practices. Feed additive formulations and in-water therapeutics align differently with broiler cycles versus layer management, creating separate product development and marketing imperatives. Transitioning between therapeutic classes within a species depends on production scale, biosecurity protocols, and retailer or processor specifications.

Considering distribution channel segmentation, the market is studied across direct sales, online pharmacies, and specialty stores, each offering distinct pathways to end users and varying degrees of technical support. Direct sales relationships often support integrated stewardship programs and formalized dosing guidance, while online pharmacies expand access but require robust digital information to preserve correct usage. Specialty stores play a key role in regions with dense independent veterinary practices and feed cooperatives, providing localized advisory services that influence product choice and adherence to recommended protocols.

Product type segmentation clarifies clinical application and resistance management strategies. The market is studied across ionophores and synthetic drugs, with ionophores further studied across lasalocid, monensin, and salinomycin, while synthetic drugs are further studied across nitrofurans, quinolones, and sulfonamides; this taxonomy highlights differing mechanisms of action, regulatory considerations, and therapeutic niches. Ionophores are commonly employed as continuous feed additives in certain production systems, whereas synthetics are more often used for targeted therapeutic courses or in rotation programs. Form-based segmentation reveals how delivery impacts adoption: the market is studied across feed additive, liquid, and premix forms, each providing trade-offs in dosing accuracy, ease of on-farm implementation, and integration with existing feed mill operations. Premix formats support centralized feed production and consistent dosing, feed additives enable continuous prophylaxis at scale, and liquids offer flexible administration in water systems for targeted interventions.

Regional insights highlighting heterogenous drivers across the Americas, Europe, Middle East & Africa, and Asia-Pacific and their implications for product strategy

Regional dynamics shape regulatory priorities, disease pressures, and procurement behavior. In the Americas, production scale, integrated supply chains, and processor-led quality programs create demand for consistent, feed-compatible anticoccidial solutions; producers often favor products that align with high-throughput systems and stringent food-safety requirements. Across Europe, Middle East & Africa, regulatory scrutiny on certain synthetic compounds and strong emphasis on antimicrobial stewardship steer product adoption toward options that balance efficacy and residue risk. Retailer commitments and welfare-driven initiatives in many European markets also influence the transition toward integrated management approaches and reduced prophylactic reliance.

Asia-Pacific presents a mosaic of production systems and regulatory environments that influence both demand and distribution models. High-density poultry production in parts of the region sustains robust demand for accessible, cost-effective anticoccidial programs, while emerging regulatory harmonization efforts are increasing expectations around residue monitoring and quality assurance. Concurrently, digital commerce and evolving veterinary services in parts of Asia-Pacific accelerate adoption of alternative distribution channels. Across regions, localized resistance profiles, feed mill density, and the prevalence of contract farming models combine to determine which product types and forms gain traction, underscoring the need for regionally adapted regulatory strategies and commercial playbooks.

Key company insights emphasizing strategic behaviors, R&D focus areas, and collaborative models shaping competitive dynamics in the anticoccidial space

Market participants exhibit diverse strategic postures that reflect their scale, portfolio breadth, and vertical integration. Large multinational animal health firms prioritize innovation in formulation stability, resistance mitigation technologies, and integrated service offerings that bundle diagnostics and stewardship programs. These organizations invest in global regulatory affairs capabilities to navigate differing residue and registration requirements and often deploy multi-channel distribution models to reach both industrial integrators and smaller independent producers. Mid-sized and regional manufacturers focus on cost-competitive formulations, local regulatory expertise, and supply chain reliability, leveraging proximity to feed mill networks and contract farming clusters.

Across the value chain, contract manufacturing and co-development partnerships have become more common as companies seek to expand capacity without incurring full-scale capital commitments. Collaborative research arrangements between pharmaceutical developers, academic institutions, and diagnostic providers aim to accelerate resistance monitoring tools and refined dosing regimens. Meanwhile, specialized feed additive firms and premix suppliers are differentiating through product customization, technical services, and superior traceability to meet the exacting needs of integrated producers. These company-level behaviors indicate a market where competitive advantage increasingly derives from combined expertise in formulation, regulatory navigation, and on-farm advisory capability rather than solely from molecule ownership.

Actionable recommendations for industry leaders to align product development, commercial strategy, and stewardship with evolving market realities

Industry leaders should prioritize integrated approaches that link product efficacy with on-farm implementation and resistance management. Investing in diagnostics and surveillance partnerships will improve the targeting of therapeutic interventions and support data-driven rotation or combination strategies that preserve efficacy. In parallel, enhancing formulation compatibility with common feed mill workflows and water medication systems will reduce barriers to adoption and improve dosing accuracy. These technical investments should be coupled with educational programs for veterinarians and feed managers to ensure correct use and to reinforce stewardship principles.

On the commercial front, firms should diversify distribution strategies to include strengthened direct-sales capabilities, partnerships with specialty providers, and compliant digital channels that expand reach while maintaining quality assurance. Companies exposed to trade-related cost volatility should evaluate nearshoring options, contractual hedging practices, and supplier diversification to preserve continuity. Finally, leaders must proactively engage regulatory stakeholders and processors on residue monitoring, labeling, and acceptable usage frameworks, because early alignment can de-risk launches and facilitate smoother market access across jurisdictions. Taken together, these measures will help reconcile commercial objectives with the imperative to maintain long-term therapeutic effectiveness.

Research methodology detailing data collection, validation processes, and analytical techniques used to ensure reliability and applicability of findings

The research draws upon a mixed-methods approach combining primary interviews, secondary literature analysis, and supply chain mapping to build a comprehensive evidence base. Primary inputs included structured interviews with veterinarians, feed mill managers, contract manufacturers, and distribution specialists to capture operational realities and adoption barriers. Secondary sources included peer-reviewed literature on coccidiosis biology and treatment efficacy, regulatory filings, product labels, and public trade documentation to corroborate technical and policy contexts.

Data were triangulated to validate trends and reconcile conflicting accounts, with iterative cross-checking between field insights and document-level evidence. Where applicable, regional regulatory databases and customs documentation were consulted to understand tariff impacts and registration constraints. Analytical techniques emphasized qualitative thematic synthesis and comparative regional analysis rather than numerical market sizing, ensuring the report provides actionable strategic intelligence while maintaining methodological transparency. Limitations include variability in reporting standards across jurisdictions and the evolving nature of resistance surveillance data, which the research addresses through conservative interpretation and clear signaling of evidence strength.

Conclusion summarizing the strategic imperatives for stakeholders operating in the anticoccidial domain and the pathways to sustainable therapeutic effectiveness

The anticoccidial landscape is being reshaped by scientific advances, regulatory pressures, shifting distribution models, and trade dynamics. Maintaining therapeutic effectiveness will require integrated strategies that link product innovation with stewardship, robust supply chain design, and targeted commercial engagement. Companies that succeed will be those that align formulation development with on-farm practices, invest in resistance monitoring partnerships, and adopt distribution models that preserve quality while expanding access.

Moving forward, stakeholders should treat resistance management and regulatory alignment as central strategic priorities rather than compliance afterthoughts. By doing so, they will protect efficacy, support animal welfare and food-safety objectives, and create differentiable value propositions for processors and producers. The combined emphasis on diagnostics, formulation compatibility, and adaptive sourcing will define competitiveness in the coming years, enabling sustainable use of anticoccidial interventions across diverse production systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anticoccidial Drugs Market, by Product Type

  • 8.1. Ionophores
    • 8.1.1. Lasalocid
    • 8.1.2. Monensin
    • 8.1.3. Salinomycin
  • 8.2. Synthetic Drugs
    • 8.2.1. Nitrofurans
    • 8.2.2. Quinolones
    • 8.2.3. Sulfonamides

9. Anticoccidial Drugs Market, by Form

  • 9.1. Feed Additive
  • 9.2. Liquid
  • 9.3. Premix

10. Anticoccidial Drugs Market, by End Use

  • 10.1. Cattle
  • 10.2. Poultry
    • 10.2.1. Broiler Chicken
    • 10.2.2. Layer Chicken
  • 10.3. Swine

11. Anticoccidial Drugs Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Anticoccidial Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anticoccidial Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anticoccidial Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anticoccidial Drugs Market

16. China Anticoccidial Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alltech, Inc.
  • 17.6. BASF SE
  • 17.7. Bayer Aktiengesellschaft
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Cargill, Incorporated
  • 17.10. Ceva Sante Animale
  • 17.11. DCBL Pharmaceuticals Ltd.
  • 17.12. Dechra Pharmaceuticals PLC
  • 17.13. Elanco Animal Health Incorporated
  • 17.14. Evonik Industries AG
  • 17.15. HIPRA S.A.
  • 17.16. Huvepharma AD
  • 17.17. Impextraco NV
  • 17.18. Intas Pharmaceuticals Limited
  • 17.19. Kemin Industries, Inc.
  • 17.20. Lallemand Inc.
  • 17.21. Merck & Co., Inc.
  • 17.22. Novus International, Inc.
  • 17.23. Nutreco N.V.
  • 17.24. Phibro Animal Health Corporation
  • 17.25. Qilu Animal Health Products Co., Ltd.
  • 17.26. V H Group
  • 17.27. Vetoquinol S.A.
  • 17.28. Virbac S.A.
  • 17.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTICOCCIDIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTICOCCIDIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LASALOCID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LASALOCID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LASALOCID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY MONENSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY MONENSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY MONENSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SALINOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SALINOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SALINOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY NITROFURANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY NITROFURANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY NITROFURANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY QUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FEED ADDITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FEED ADDITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY FEED ADDITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PREMIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PREMIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY PREMIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY BROILER CHICKEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY BROILER CHICKEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY BROILER CHICKEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LAYER CHICKEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LAYER CHICKEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY LAYER CHICKEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTICOCCIDIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY IONOPHORES, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ANTICOCCIDIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)